Rutgers University (Camden)

Michael A. Carrier

Rutgers University (Camden)
Professor of Law

Michael A. Carrier is Distinguished Professor at Rutgers Law School, where he specializes in antitrust and IP law. He is co-author of the leading IP/antitrust treatise, IP and Antitrust Law : An Analysis of Antitrust Principles Applied to Intellectual Property Law, the author of Innovation for the 21st Century : Harnessing the Power of Intellectual Property and Antitrust Law, and the editor of Critical Concepts in Intellectual Property Law : Competition. He has written more than 120 book chapters and articles in leading law reviews, has been quoted more than 2000 times in the media, and has been cited in courts including the U.S. Supreme Court. Professor Carrier has testified before the FDA, FTC, National Academies, Senate Judiciary Committee, and House Energy & Commerce Committee ; is a past chair of the Executive Committee of the Antitrust and Economic Regulation section of the Association of American Law Schools (AALS) ; was a policy volunteer for the 2020 Biden-Harris campaign ; and served on the 2016 ABA Antitrust Section’s Presidential Transition Task Force.

Distinctions

Vidéos

Michael Carrier
Michael A. Carrier 28 mars 2017 Washington, DC

Articles

9970 Bulletin

Michael A. Carrier The US Court of Appeals for the Federal Circuit reverses a judgment that upheld “skinny labels” and allowed a generic to launch on uses not covered by a patent (GlaxoSmithKline / Teva)

55

On October 2, 2020, the U.S. Court of Appeals for the Federal Circuit vacated a district court’s judgment in favor of defendant Teva in a case involving “skinny labels.” GlaxoSmithKline LLC v. Teva Pharm. USA, Inc., 976 F.3d 1347 (Fed. Cir. 2020). When a drug can be used to treat multiple (...)

Michael A. Carrier Antitrust in the pharmaceutical sector : An overview of US case law

1150

The issues presented by pharmaceutical antitrust law are vital to national economies and patients’ lives. They implicate patent law, antitrust law, and various regulations. They occur in unique markets in which the entity prescribing the drug is not the one paying for it. And they rely on patents but also are marked by complexity, which creates room for anticompetitive conduct. The articles in this symposium shed light on these topics.

Michael A. Carrier The US District Court for the Northern District of California finds that an athletics association’s rules restricting payments to student-athletes violate antitrust laws (O’Bannon / NCAA)

392

On August 8, 2014, in O’Bannon v. National Collegiate Athletic Association (NCAA), Judge Claudia Wilken of the U.S. District Court for the Northern District of California found that the NCAA violated the antitrust laws by enacting rules that prevented student-athletes from being paid for the use (...)

Michael A. Carrier The US District Court for the Western District of Washington issues first analysis of an appropriate royalty that a patentee could obtain after promising to license its patent on reasonable and nondiscriminatory (RAND) terms (Microsoft / Motorola)

434

On April 25, 2013, Judge James L. Robart of the U.S. District Court for the Western District of Washington offered the first analysis by a U.S. court of an appropriate royalty that a patentee could obtain after promising to license its patent on reasonable and nondiscriminatory (RAND) terms. (...)

5108 Revue

Alden F. Abbott, Robin Adelstein, Megan Browdie, Michael A. Carrier, Peter Carstensen, Samuel Clark, Lisl J. Dunlop, Harry First, Albert A. Foer, Eleanor M. Fox, Jacqueline Grise, Ryan Kantor, Donald C. Klawiter, John Kwoka, James Langenfeld, Tad Lipsky, Alessandro Massolo, Howard Morse, Gabriella Muscolo, James Bo Pearl, Noah Pinegar, Chris Ring, Christopher Sagers, Richard S. Taffet, Willard K. Tom, Eliot Turner, Doug Tween, Tommaso Valletti, Michael L. Weiner The new US antitrust administration

3000

Ce dossier Concurrences se concentre sur l’antitrust et ses possibles développements à la suite des élections présidentielles américaines. Il s’interroge sur les changements et défis attendus pour 2021 sous la nouvelle administration Biden, et leurs impacts sur la législation et la politique de la (...)

Agathe Richard, Aidan Synnott, Albert A. Foer, Alden F. Abbott, Alvaro Ramos, Ben Labow, Bonny Sweeney, Bradley T. Tennis, Christopher Meyers, Donald C. Klawiter, James J. Tierney, James Langenfeld, Janet McDavid, John DeQ. Briggs, John Kwoka, Joseph Farrell, Logan M. Breed, Mark D. Whitener, Michael A. Carrier, Michael D. Hausfeld, Michael L. Weiner, Michael P. Lehmann, Richard S. Taffet, Scott Andrew Sher, Sharis A. Pozen, William H. Rooney What is Trump Antitrust ?

2108

Il y a du changement dans l’air aux Etats-Unis, et ce changement va impacter la politique antitrust et celle de la concurrence. L’élection inattendue du nouveau président-élu Donald J. Trump a ouvert la porte à des spéculations et à l’inconnue de ce que sera la politique de concurrence envisagée par (...)

Livres

Prix 230€00 Albert A. Foer Liber Amicorum

At a time of reckoning for the future of antitrust, this Liber Amicorum brings together a diverse collection of today’s leading thinkers to pay tribute to Albert Allen (Bert) Foer, founder of the (...)

Date 14 octobre 2020
Auteur(s) : Nicolas Charbit, Sonia Ahmad (Editors)
Prix 230€00
Consulter en ligne
Envoyer un message